Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous close | 13.03 |
| Open | 13.21 |
| Bid | 13.33 x 4000 |
| Ask | 13.34 x 1400 |
| Day's range | 13.19 - 13.38 |
| 52-week range | 12.77 - 16.39 |
| Volume | |
| Avg. volume | 1,567,880 |
| Market cap | 41.893B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 46.03 |
| EPS (TTM) | 0.29 |
| Earnings date | 31 July 2024 |
| Forward dividend & yield | 0.64 (4.78%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | 18.31 |
Business WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK, June 01, 2024--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and at the 29th European Hematology Association (EHA) Annual Meeting (S225). Th
Business WireTakeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass., May 31, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP. The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for rAD
Business WireTakeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass., May 14, 2024--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill.
